Serent Capital Backs United Allergy Services

Growth equity firm Serent Capital has backed San Francisco-based United Allergy Services, a provider of allergy testing and immunotherapy services to primary care physicians. Financial details were not disclosed.


Serent Capital, a growth equity firm focused on investing in rapidly expanding businesses, announced today an investment in United Allergy Services (“UAS”), the leading provider of allergy testing and immunotherapy services to primary care physicians. Since its founding in 2009, UAS has been changing the treatment of seasonal allergies by expanding access to treatment via primary care physicians.
According to Nick Hollis, the CEO of UAS, “Serent Capital was selected as an equity partner for its hands on skills in assisting management tackle a hyper-growth services business. With a Rolodex and a combination of consulting and operating skills, the Serent team provides the ideal mix of analysis, theory and practice. By participating side by side with management in the leveraged buy down of the founding owners, and working closely with us to build the Company, the Serent team is a true partner in the business not just a financial investor. We could not have asked for more.”
Serent’s principals have substantial experience with healthcare services and innovations in primary care, which led to its decision to invest in UAS and will support the Company going forward. “UAS has created a new model to increase access to immunotherapy for the more than 60 million sufferers in the U.S., a population that is dramatically under-utilizing this therapy today” said David Kennedy, co-founder and General Partner of Serent Capital. “The Company’s offering provides a compelling value proposition for all stakeholders, including patients, primary care providers and payers. We are excited to partner with Nick and the Company to continue building on UAS’ success to date.”

About United Allergy Services
Headquartered in San Antonio, TX, United Allergy Services™ (UAS) brings effective and convenient allergy testing and immunotherapy to primary care physicians; pulmonologists; ENT physicians; pediatricians; internal medicine physicians; and healthcare systems that treat the vast majority of patients with seasonal and perennial allergies. UAS’ complete service line features in-office UAS Certified Clinical Allergy Specialist staffing and training; quality assurance and regulatory compliance; and supply and inventory management. By empowering physicians to safely administer allergy testing and immunotherapy treatment, UAS has effectively expanded access to immunotherapy to more than 60 million U.S. residents currently suffering from seasonal and perennial allergies.

About Serent Capital
Serent Capital invests in growing businesses that have developed compelling solutions that address their customers’ needs. As those businesses grow and evolve, the opportunities and challenges that they face evolve with it. Principals at Serent Capital have firsthand experienced at capturing those opportunities and navigating the challenges through their experiences as CEOs, strategic advisors, and board members to successful, growing businesses. By bringing our experience and capital to bear, Serent helps growing businesses thrive.